LifeVantage at Water Tower Research Virtual Insights Conference: turnaround focus

On September 23, 2026, LifeVantage (LFVN) discussed its turnaround strategy at the Water Tower Research Virtual Insights Conference. The new Chief Executive Terrence Moorehead outlined three key priorities: strengthening the brand, creating a more consumer-centric approach, and improving operational efficiency.

Recent sales weakness and margin pressure have impacted LifeVantage, with revenue weaker over the past 12 to 18 months, compressing EBITDA margins in fiscal 2026. The company's gross margin remains near 80%, but its SG&A expense ratio has risen to 32% of revenue, resulting in about $10 million in cost cuts so far.

The company remains debt-free and generates substantial free cash flow, but has taken steps to cut costs while maintaining its dividend and share repurchase programs. LifeVantage emphasizes its science-based supplements, which activate the body's natural defense mechanisms, as distinct from standard supplements.

Management highlighted three products in the portfolio: Protandim Nrf2 (cellular defense), Protandim Nrf1 (cellular energy), and Protandim NAD (longevity). Despite clinical proof, the company has not effectively promoted these advantages.

Moorehead stressed the importance of a stronger brand, a more relevant consumer proposition, and better efficiency and profitability. The company believes in digital marketing, product repositioning, and exploring opportunities in Japan and Mexico, while maintaining its dividend and share repurchases.

The company's MindBody GLP-1 System experienced explosive growth in fiscal 2025 but has since slowed. The decline is attributed to competitive pressure, new product forms, price moderation, and insufficient new customer acquisition. The company aims to reposition MindBody around its clinical proof and natural positioning, prioritizing the U.S. market before expanding abroad.